Table 2.
Participant characteristics.
| EAP | BPS | EABP | PP | CON | |
|---|---|---|---|---|---|
| No. of participants | 25 | 13 | 15 | 6 | 26 |
| Age | 34 (22-50) | 46 (27-51) | 31 (20-51) | 31 (25-34) | 29.5 (21-45) |
| Current pain intensity | 1 (0-6) | 3 (0-8) | 2 (0-7) | 0 (0-2) | 0 (0-2) |
| Duration of pain (y) | 18 (7-33) | 19 (0-37) | 21 (6-35) | 17 (11-22) | — |
| painDETECT score | 9.2 (0-18) | 14.6 (2-29) | 14 (7-26) | 9 (3-13) | N/A |
| painDETECT neuropathic, n (% of group) | 0 (0) | 5 (41.7) | 3 (23.1) | 0 (0) | N/A |
| painDETECT mixed n (% of group) |
4 (23.5) | 1 (8.3) | 5 (38.5) | 1 (16.7) | N/A |
| painDETECT nociceptive n (% of group) | 13 (76.5) | 6 (50) | 5 (38.5) | 5 (83.3) | N/A |
| State anxiety score | 32.1 (20-49) | 41 (20-67) | 33 (22-56) | 28.5 (20-43) | 26 (20-41) |
| Menstrual phase n (% of group) |
|||||
| Menstrual | 2 (8) | 0 (0) | 0 (0) | 1 (16.7) | 4 (16) |
| Proliferative | 1 (4) | 0 (0) | 1 (6.7) | 0 (0) | 4 (16) |
| Secretory | 2 (8) | 1 (8.3) | 2 (13.3) | 2 (33.3) | 3 (12) |
| Taking steroid hormones n (% of group) |
20 (80) | 9 (75) | 12 (80) | 3 (50) | 12 (48) |
| Medications n (% of group) |
|||||
| NSAIDS | 1 (4) | 0 (0) | 2 (13.3) | 1 (16.7) | 1 (3.8) |
| Other over-the-counter painkillers (eg, paracetamol) | 3 (12) | 1 (7.7) | 3 (20) | 0 (0) | 0 (0) |
| Antidepressants/Anxiolytics | 8 (32) | 6 (46.2) | 7 (46.7) | 2 (33.3) | 6 (23.1) |
| Medications for other health conditions (eg, allergy medication) | 15 (60) | 6 (46.2) | 9 (60) | 2 (33.3) | 12 (46.2) |
| Vitamins/minerals/probiotics/herbal | 5 (20) | 1 (7.7) | 2 (13.3) | 0 (0) | 7 (26.9) |
| Opioids | 1 (4) | 0 (0) | 1 (6.7) | 0 (0) | 0 (0) |
| Muscle relaxants | 1 (4) | 2 (15.4) | 0 (0) | 0 (0) | 0 (0) |
| Gabapentinoids | 1 (4) | 0 (0) | 1 (6.7) | 0 (0) | 0 (0) |
| Surgery to diagnose/exclude endometriosis n (% of group) |
25 (100) | 0 (0) | 14 (100) | 2 (33.3) | 0 (0) |
| Stage of endometriosis n (% within those who have had surgery to diagnose/exclude endometriosis) |
|||||
| Stage I | 9 (36) | 0 (0) | 7 (46.7) | 0 (0) | — |
| Stage II | 4 (16) | 0 (0) | 3 (20) | 0 (0) | — |
| Stage III | 2 (8) | 0 (0) | 1 (6.7) | 0 (0) | — |
| Stage IV | 6 (24) | 0 (0) | 2 (13.3) | 0 (0) | — |
| Stage unknown | 4 (16) | 0 (0) | 2 (13.3) | 0 (0) | — |
| No endometriosis | 0 (0) | 0 (0) | 0 (0) | 0 (0) | — |
Shown are participant demographics for each of the TRiPP subgroups: EAP (endometriosis-associated pain), BPS (bladder pain and urinary symptoms), EABP (comorbid endometriosis and bladder symptoms), PP (pelvic pain without endometriosis or bladder symptoms), and CON (controls without pelvic pain or endometriosis). Age is given in years with mean and range. Pain intensity is given as median score on 0 to 10 NRS scale with range. Duration of pain is given in years as a median score with range; for the CON group, this is not applicable as they are pain free. Current state anxiety score is given as a mean and range based on State-Trait Anxiety Inventory—State Questionnaire,60 scores of 20 to 39, 40 to 59, and 60 to 80 indicate low, moderate, and high anxiety, respectively. painDETECT25 score is given as mean and range. Medications taken in the 24 hours before the study visit, as broken down to medication groups are shown as counts. Surgery to diagnose or exclude endometriosis is given as counts and percentages per group. The stage of endometriosis shown as count and percentage of those who had received surgery to diagnose or exclude endometriosis.